| GTO ID | GTC2812 |
| Trial ID |
NCT05079633
|
| Disease |
Adverse Reaction to Vaccine
|
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1273|Elasomeran|Spikevax |
| Location approved | UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Phase | Phase4 |
| Recruitment status | Unknown |
| Title | A Parallel Group, Prospective, Randomized, Double-blind, Two-arm, Single-center Study to Evaluate the Immunogenicity, Safety, and Tolerability of mRNA-1273 in Heterologous Prime-Boost With MVC-COV1901 in Adult Volunteers of 20 to 70 Years |
| Year | 2021 |
| Country | China |
| Company sponsor | National Taiwan University Hospital |
| Other ID(s) | 202108058MINB |